State of the art of Smo antagonists for cancer therapy: Advances in the target receptor and new ligand structures

Keyphrases

• Cancer Therapy 100%
• Ligand-receptor Binding 100%
• New Ligand 100%
• Smo Receptor 100%
• Target Receptor 100%
• Ligand Structure 100%
• Clinical Trials 50%
• Therapeutic Target 50%
• Chemical Structure 50%
• US FDA-approved Drugs 50%
• Hedgehog Proteins 50%
• Hedgehog Signaling Pathway 50%
• Receptor Structure 50%
• Vismodegib 50%
• Medulloblastoma 50%
• Basal Cell Carcinoma 50%
• Clinical Limitations 50%
• Sonidegib 50%

Medicine and Dentistry

• Receptor 100%
• Cancer Therapy 100%
• Clinical Trial 50%
• Malignant Neoplasm 50%
• Signal Transduction 50%
• G Protein Coupled Receptor 50%
• Hedgehog Signaling 50%
• Medulloblastoma 50%
• Basal-Cell Carcinoma 50%
• Receptor Structure 50%
• Sonidegib 50%
• Vismodegib 50%
• Sonic Hedgehog Protein 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Receptor 100%
• Malignant Neoplasm 100%
• Clinical Trial 33%
• G Protein Coupled Receptor 33%
• Basal Cell Carcinoma 33%
• Medulloblastoma 33%
• Sonidegib 33%
• Hedgehog 33%
• Vismodegib 33%
• Sonic Hedgehog Protein 33%